Postmarketing Cases of Enfortumab Vedotin–Associated Skin Reactions Reported as Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis
Open Access
- 8 September 2021
- journal article
- letter
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 157 (10) , 1237-1239
Abstract
During routine surveillance, the US Food and Drug Administration (FDA) Division of Pharmacovigilance identified postmarketing cases of Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN) associated with enfortumab vedotin (EV) from the FDA Adverse Event Reporting System (FAERS). To investigate a potential association between EV and SJS/TEN, we evaluated all sources for postmarketing cases of SJS/TEN and report our findings.Keywords
This publication has 3 references indexed in Scilit:
- Case Report: Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Case Series on the Clinical and Histopathologic Spectrum of Adverse Cutaneous Reactions From Fatal Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis to Dermal Hypersensitivity ReactionFrontiers in Oncology, 2021
- A rare presentation of enfortumab vedotin–induced toxic epidermal necrolysisJAAD Case Reports, 2021
- Epidemiology of Locally Advanced or Metastatic Urothelial Cancer In The US, Europe And JapanValue in Health, 2017